# US 2026/0008748 A1 · Compounds with biguanidyl radical and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0008748 A1
- Document ID: US20260008748A1
- Status: Published application
- Kind: A1
- Application number: 19/326,920
- Filed: 2025-09-12
- Published: 2026-01-08
- Earliest claimed: 2018-06-05
- Assignees: Institut Curie; Institut National de la Sante et de la Recherche Medicale; Centre National De La Recherche Scientifique
- Applicants: Institut Curie; Institut National De La Santé Et De La Recherche MéDicale; Centre National De La Recherche Scientifique
- Inventors: TATIANA CAÑEQUE; SEBASTIAN MÜLLER; RAPHAËL RODRIGUEZ
- Web page: https://patentgrep.com/patent/US20260008748A1

## CPC

- C07C 279/265: {containing two or more biguanide groups}
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07F 9/5442: {Aromatic phosphonium compounds (P-C aromatic linkage)}
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention relates to new compounds of formula (I), and their uses.

## Claims

### Claim 1

A compound of formula (I)
wherein
R1 is selected from the group consisting of a C1-C6 alkyl, —(CH2)a—C≡CH, —(CH2)b—P+Ph3, a C3-C10 cycloalkyl, a C3-C10 cycloheteroalkyl, a C6-C12 aryl, and a C5-C12 heteroaryl, with “a” being an integer selected from 1 to 6 and “b” being an integer selected from 5 to 11 said alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl being optionally substituted by a R group or a R′ group; and
R2 is selected from the group consisting of
—(CH2)a—C≡CH, with “d” being an integer selected from 1 to 6; and
—(CH2)e—CH═CH2 with “e” being an integer selected from 2 to 6;
or
R1 is selected from the group consisting of H, a C1-C6 alkyl, —(CH2)a-C≡CH, —(CH2)b—P+Ph3, a C3-C10 cycloalkyl, a C3-C10 cycloheteroalkyl, a C6-C12 aryl, and a C5-C12 heteroaryl, with “a” being an integer selected from 1 to 6 and “b” being an integer selected from 5 to 11, said alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl being optionally substituted by a R group or a R′ group;
R2 is selected from the group consisting of
—(CH2)f—CR4═CH—CH═CR5—(CH2)g—R3 with R4 and R5 being H, a R group or forming together a six-member ring, optionally substituted by one or two R′ groups or fused with a cycloalkyl, an aryl, a cycloheteroalkyl or a heteroaryl having 3 to 6 members, “f” and “g” being an integer independently selected from 1 to 3;
—(CH2)f—C≡C—C≡C—(CH2)g—R3, with “f” and “g” being an integer independently selected from 1 to 3;
—(CH2)i—R3, with “i” being an integer selected from 7 to 9;
—(CH2)j—CH[(CH2)k—P+Ph3]—(CH2)l—R3 with “j” and “l” being integer independently selected from 1 to 6, and “k” being an integer selected from 1 to 6;
—(CH2)m-cyclobutanyl-(CH2)n—R3 with “m” and “n” being an integer independently selected from 1 to 3; and
—(CH2)p—CHR6—CH═CH—CHR7—(CH2)q—R3 with R6 and R7 being H, a R group or forming together a 4-6 member ring, optionally substituted by one or two R′ groups or fused with a cycloalkyl, an aryl, a cycloheteroalkyl or a heteroaryl having 3 to 6 members, “p” and “q” being an integer independently selected from 1 to 3; and
R3 is
with R8 selected from the group consisting of H, a C1-C6 alkyl, —(CH2)a—C≡CH, —(CH2)b—P+Ph3, a C3-C10 cycloalkyl, a C3-C10 cycloheteroalkyl, a C6-C12 aryl, and a C5-C12 heteroaryl, with “a” being an integer selected from 1 to 6 and “b” being an integer selected from 5 to 11 said alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl being optionally substituted by a R group or a R′ group;
wherein
R is selected from the group consisting of a C1-C6 alkyl, a C1-C6 alkyloxy, a C1-C6 halogenoalkyl, a C3-C10 cycloalkyl, a C3-C10 cycloheteroalkyl, a C6-C12 aryl, and a C5-C12 heteroaryl, the group being optionally substituted by a group R′,
R′ is selected from the group consisting of a C1-C6 alkyl, a C1-C6 alkyloxy, a C1-C6 thioalkyl, a halogen, a C1-C6 halogenoalkyl, a hydroxyl (—OH), a cyano (—CN), a nitro, an amino (—NH2), a carboxyl (—COOH), a phosphate (PO4−), an amide (—CONH2), —COOR″, —NHR″, —NR″R″′, —COR″, —CONHR″, —NHCOR″, —NHSO2R″, —SOR″, —SO2R″, —SONR″R″′, —SO2NR″R′, a C3-C10 cycloalkyl, a C3-C10 cycloheteroalkyl, a C6-C12 aryl, and a C5-C12 heteroaryl, said cycloalkyl, cycloheteroalkyl, aryl or heteroaryl being optionally substituted by a halogen, a hydroxyl, a cyano, a nitro, an amino, or a C1-C3 alkoxy, with R″ and R′″ being H or a C1-C6 alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R3 is present in the compound.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R2 is selected from the group consisting of
—(CH2)d—C≡CH, with “d” being an integer selected from 2 to 4;
—(CH2)e—CH═CH2 with “e” being an integer selected from 2 to 4;
—(CH2)f—CR4═CH—CH═CR5—(CH2)g—R3 with R4 and R5 being H, a R group or forming together a six-member ring, optionally substituted by one or two R′ groups or fused with a cycloalkyl, an aryl, a cycloheteroalkyl or a heteroaryl having 3 to 6 members, “f” and “g” being an integer independently selected from 1 to 3, and “f”+“g” being from 2 to 4;
—(CH2)f—C≡C—C≡C—(CH2)g—R3, with “f” and “g” being an integer independently selected from 1 to 3, and “f”+“g” being from 2 to 4;
—(CH2)i—R3, with “i” being an integer selected from 7 to 9;
—(CH2)j—CH[(CH2)k—P+Ph3]—(CH2)l—R3 with “j” and “l” being integer independently selected from 1 to 6, and “j”+“l” being from 5 to 7 and “k” being an integer selected from 2 to 4;
—(CH2)m-cyclobutanyl-(CH2)n—R3 with “m” and “n” being an integer independently selected from 1 to 3, and “m+n” being from 2 to 4; and
—(CH2)p—CHR6—CH═CH—CHR7—(CH2)q—R3 with R6 and R7 being H, a R group or forming together a 4-6 member ring, optionally substituted by one or two R′ groups or fused with a cycloalkyl, an aryl, a cycloheteroalkyl or a heteroaryl having 3 to 6 members, “p” and “q” being an integer independently selected from 1 to 3, and “p”+“q” being from 2 to 4.

### Claim 4 (depends on 1)

The compound of claim 1, wherein
R1 is selected from the group consisting of a methyl, —(CH2)a—C≡CH and —(CH2)b—P+Ph3, with “a” being an integer selected from 2 to 4, and “b” being an integer selected from 6 to 10; and
R2 is selected from the group consisting of
—(CH2)d—C≡CH, with “d” being an integer selected from 2 to 4; and
—(CH2)e—CH═CH2 with “e” being an integer selected from 2 to 6.

### Claim 5 (depends on 1)

The compound of claim 1, wherein
R1 is selected from the group consisting of H, a methyl, —(CH2)a—C≡CH and —(CH2)b—P+Ph3, with “a” being an integer selected from 2 to 4, and “b” being an integer selected from 6 to 10;
R2 is selected from the group consisting of
—(CH2)f—CR4═CH—CH═CR5—(CH2)g—R3 with R4 and R5 being H, “f” and “g” being an integer independently selected from 1 to 3, and “f”+“g” being from 2 to 4;
—(CH2)f—C≡C—C≡C—(CH2)g—R3, with “f” and “g” being an integer independently selected from 1 to 3 and “f” + “g” being from 2 to 4;
—(CH2)i—R3, with “i” being an integer selected from 7 to 9;
—(CH2)j—CH[(CH2)k—P+Ph3]—(CH2)l—R3 with “j” and “l” being integer independently selected from 1 to 6, “j”+“l” being from 5 to 7, and “k” being an integer selected from 1 to 6;
—(CH2)m-cyclobutanyl-(CH2)n—R3 with “m” and “n” being an integer independently selected from 1 to 3 and “m+n” being from 2 to 4; and
—(CH2)p—CHR6-CH═CH—CHR7—(CH2)q—R3 with R6 and R7 being H or forming together a 4-member ring, “p” and “q” being an integer independently selected from 1 to 3 and “p”+“q” being from 2 to 4; and
R3 is
with R8 selected from the group consisting of H, a methyl, (CH2)a—C≡CH and —(CH2)b—P+Ph3, with “a” being an integer selected from 1 to 6 and “b” being an integer selected from 5 to 11.

### Claim 6 (depends on 1)

The compound of claim 1, wherein at least one among R1, R2 and R8 is —(CH2)a—C≡CH with “a” being an integer from 1 to 6.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of
with n being an integer selected from 3 to 9;
with n being independently an integer selected from 0 to 5;
with n being independently an integer selected from 0 to 5;
wherein
the dotted line being present or absent and being one or two atoms with covalent bonds; and
R is selected from the group consisting of a C1-C6 alkyl, a C1-C6 alkyloxy, a C1-C6 halogenoalkyl, a C3-C10 cycloalkyl, a C3-C10 cycloheteroalkyl, a C6-C12 aryl, and a C5-C12 heteroaryl, the group being optionally substituted by a group R′; R′ being selected from the group consisting of a C1-C6 alkyl, a C1-C6 alkyloxy, a C1-C6 thioalkyl, a halogen, a C1-C6 halogenoalkyl, a hydroxyl (—OH), a cyano (—CN), a nitro, an amino (—NH2), a carboxyl (—COOH), a phosphate (PO4−), an amide (—CONH2), —COOR″, —NHR″, —NR″R″′, —COR″, —CONHR″, —NHCOR″, —NHSO2R″, —SOR″, —SO2R″, —SONR″R″′, —SO2NR″R″′, a C3-C10 cycloalkyl, a C3-C10 cycloheteroalkyl, a C6-C12 aryl, and a C5-C12 heteroaryl, said cycloalkyl, cycloheteroalkyl, aryl or heteroaryl being optionally substituted by a halogen, a hydroxyl, a cyano, a nitro, an amino, or a C1-C3 alkoxy, with R″ and R″′ being H or a C1-C6 alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of
with n being an integer selected from 3 to 9; and
with n being an integer independently selected from 0 to 5, or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

A conjugate obtained by reacting a compound of claim 1 and having an alkyne group with a drug, a toxin or a label covalently linked to an azide (N3) group.

### Claim 10 (depends on 1)

A pharmaceutical or veterinary composition comprising a compound of claim 1, said compound having an alkyne group and optionally, being covalently conjugated to a drug, a toxin or a label via an azide (N3) group.

### Claim 11 (depends on 10)

The pharmaceutical or veterinary composition of claim 10 further comprising another drug.

### Claim 12 (depends on 11)

The pharmaceutical or veterinary composition of claim 11, said drug being selected from the group consisting of chemotherapeutic agents, anti-cancer antibodies, hormone therapy agents, immunotherapeutic agents, kinase inhibitors and combinations thereof.
